A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)

PHASE3CompletedINTERVENTIONAL

Enrollment

676

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions

Obesity

Interventions

DRUG

VI-0521

7.5 mg phentermine and 46 mg topiramate

DRUG

Placebo

placebo

DRUG

VI-0521

15 mg phentermine and 92 mg topiramate